Literature DB >> 1665577

Type RI resistance to halofantrine in West Africa.

L K Basco1, J Le Bras, C Gillotin, P Ringwald, E Rabenjarson, F Gimenez, O Bouchaud, R Farinotti, J P Coulaud.   

Abstract

A case of recrudescent falciparum malaria after halofantrine treatment is described. The patient contracted Plasmodium falciparum in Ivory Coast and was treated with halofantrine. Plasma levels of halofantrine and its metabolite were adequate. Thirty-one days after treatment, the patient was rehospitalized with symptoms of malaria. Recrudescence was confirmed by microscopic examination, indicating a type RI resistance to halofantrine. Mefloquine was given to treat recrudescent malaria. The parasite was susceptible to chloroquine and quinine in vitro but displayed elevated values of 50% inhibitory concentration for mefloquine and halofantrine. The case reminds us that chloroquine still has an important therapeutic role against African strains of P. falciparum and that mefloquine and halofantrine should be reserved for multi drug-resistant P. falciparum.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1665577

Source DB:  PubMed          Journal:  Trop Med Parasitol        ISSN: 0177-2392


  2 in total

1.  Effect of a single oral dose of Fansidar on the pharmacokinetics of halofantrine in healthy volunteers: a preliminary report.

Authors:  F W Hombhanje
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

2.  Dihydroethanoanthracene derivatives as in vitro malarial chloroquine resistance reversal agents.

Authors:  Julie Millet; Marylin Torrentino-Madamet; Sandrine Alibert; Christophe Rogier; Christiane Santelli-Rouvier; Joel Mosnier; Eric Baret; Jacques Barbe; Daniel Parzy; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.